JOHN L. HIGGINS - 01 Nov 2022 Form 4/A - Amendment Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for John L. Higgins
Issuer symbol
LGND
Transactions as of
01 Nov 2022
Net transactions value
$0
Form type
4/A - Amendment
Filing time
07 Nov 2022, 19:29:50 UTC
Date Of Original Report
03 Nov 2022
Previous filing
31 Oct 2022
Next filing
21 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LGND Common Stock 426,731 01 Nov 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Form 4 filed on November 3, 2022 inadvertently understated the amount of shares beneficially held in column 5 by 2,000 shares. The number reported herein is correct.